In Sanford, Florida today, prosecutors continue making their case against George Zimmerman, the neighborhood watch volunteer who last year shot and killed teenager Trayvon Martin. Zimmerman is charged with second degree murder. In opening statements yesterday, prosecutors described Zimmerman as a vigilante who wanted to rid his neighborhood of people who didn't belong there.
Zimmerman's lawyers say he acted in self-defense. From Sanford, NPR's Greg Allen reports.
Researchers in the Great Lakes are trying to control an ancient fish, the sea lamprey. The species is notorious for latching onto other fish and literally sucking the life out of them. The lamprey larvae can be killed with a special poison, and now one biologist thinks he's found a way to make sure they're in the right place at the right time to die.
This is MORNING EDITION from NPR News. Good morning. I'm David Greene.
RENEE MONTAGNE, HOST:
And I'm Renee Montagne.
The U.S. Supreme Court surprised just about everyone yesterday with its decision on affirmative action in higher education. That surprise was an apparent compromise that leaves affirmative action programs intact for now but subjects them to a more rigorous review by the courts.
The vote was seven to one, as NPR's legal affairs correspondent Nina Totenberg reports.
And the Supreme Court was actually already having a busy week. Yesterday it handed down rulings in two other notable cases, both dealing with worker's rights. The justices split five to four along ideological lines to make it harder for employees to win discrimination lawsuits. The court raised new hurdles for plaintiffs who say they were victims of bias and then faced retaliation for raising the issue. NPR's Carrie Johnson has more.
When the blood pressure drug Bystolic hit the market in 2008, it faced a crowded field of cheap generics.
So its maker, Forest Laboratories, launched a promotional assault on the group in the best position to determine Bystolic's success: those in control of prescription pads. It flooded the offices of health professionals with drug reps, and it hired doctors to persuade their peers to choose Bystolic — even though the drug hadn't proved more effective than competitors.